NCT06461182 Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
| NCT ID | NCT06461182 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Koo Foundation Sun Yat-Sen Cancer Center |
| Condition | Indolent B-Cell Non-Hodgkin Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-04-29 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 15 participants in total. It began in 2024-04-29 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.
Eligibility Criteria
Inclusion Criteria: * The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma. * Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group. * Able to lie flat for at least 30 minutes. * Signing the subject consent form. * ECOG grade 0-2. * The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution. Exclusion Criteria: * Pregnant woman * Severe renal impairment (eGRF\< 30ml/min) * Known or suspected allergy to radiopharmaceuticals * Concurrent or previous diagnosis of malignancies other than lymphoma * Inability to undergo the necessary PET scan procedure * Refusal or unwillingness to sign the informed consent form * Severe medical conditions (severe disabilities, mental disorders)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06461182 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 100 Years, studying Indolent B-Cell Non-Hodgkin Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06461182 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06461182 currently recruiting?
Yes, NCT06461182 is actively recruiting participants. Contact the research team at yuyi@kfsyscc.org for enrollment information.
Where is the NCT06461182 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06461182 clinical trial?
NCT06461182 is sponsored by Koo Foundation Sun Yat-Sen Cancer Center. The trial plans to enroll 15 participants.